目前对心脏纤维化进行实验和早期研究的药物:我们在哪里?
Claudio M Ciampi1, Andrea Sultana1, Paolo Ossola1
1Health Science Department, University of Milan Bicocca, Milano, Italy.
Expert opinion on investigational drugs
|March 1, 2024
概括
心肌纤维化 (MF) 是一种复杂的疾病,有各种原因和表现. 目前的心力衰竭治疗提供了一些好处,但需要针对炎症和纤维化进展的新疗法.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 心肌纤维化 (MF) 是心脏病的病理标志,由各种因素驱动,包括炎症,缺血症,高血压和衰老.
- 多发性纤维的发展和特征有很大差异,表明多个潜在的治疗点.
- 现有的心力衰竭治疗主要针对神经激素激活,有限的直接向纤维化和炎症.
研究的目的:
- 审查目前用于心肌纤维化临床实践中的抗纤维化药物.
- 描述针对特定纤维细胞通路的新兴治疗剂.
- 综合新型抗纤维菌策略的临床前和临床研究的证据.
主要方法:
- 临床试验和临床前研究的文献综述.
- 对针对亲纤维细胞通路的药物机制的分析.
- 检查炎症途径和免疫细胞在心脏纤维化中的作用.
主要成果:
- 虽然RAAS抑制剂表现出一些抗纤维性作用,但许多当前的心力衰竭药物并不直接向炎症或纤维化.
- 在有希望的临床前发现和对新型抗纤维菌剂的有限临床试验之间存在差距.
- 新兴研究强调了免疫细胞和细胞因子在心脏损伤和修复中的复杂作用.
结论:
- 针对特定的炎症和纤维化通路对新型心肌纤维化治疗有希望.
- 进一步的临床研究对于验证新兴抗纤维菌疗法的疗效至关重要.
- 更深入地了解免疫系统在心脏纤维化中的作用,对于开发有效的干预措施至关重要.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429